Affiliation:
1. Main Military Clinical Hospital of the National Guard Troops of the Russian Federation
2. I. I. Mechnikov Scientific Research Institute of Vaccines and Serums
3. Samara State Medical University
4. I. M. Sechenov First Moscow State Medical University (Sechenov University)
Abstract
Community-acquired pneumonia is one of the most common acute infectious diseases, especially in organized groups. Community-acquired pneumonia in military personnel is a serious problem of the medical service and is diagnosed 2–3 times more often than among civilians. The purpose of the study. To study the clinical features of the action of “Immunovac-VP-4 ®” in the complex treatment of community-acquired pneumonia in new recruits. Materials and methods. The study group included 88 conscripted military personnel from among the new recruits who were hospitalized with a diagnosis of mild community-acquired pneumonia. The main group of the study included 35 patients receiving basic antibacterial therapy in combination with the therapeutic vaccine “Immunovak-VP-4 ®”. The control group included 53 patients who received only standard basic antibacterial therapy. Results. In the main study group, the frequency of repeated respiratory infections in all nosologies was lower than in the control group, statistically significant differences were noted in relation to pneumonia and acute rhinosinusitis. A decrease in the level of IL-1β in blood serum was revealed after 15 days (p = 0.05) and 6 months after discharge from the hospital (p = 0.002) in the main group compared with the control group. After 15 days, in the group of patients receiving “Immunovak-VP-4 ®”, there was a decrease in IL-6 levels relative to the baseline (p = 0.04) and it became lower than the control group (p = 0.04). Conclusion. The use of the “Immunovak-VP-4 ®” vaccine can be considered as a way to improve the treatment of community-acquired pneumonia: it can be a drug for treatment, prevention of complications, and an instrument in immunorehabilitation. The use of “Immunovak-VP-4 ®” in the complex treatment of community-acquired pneumonia of mild course is accompanied by a decrease in the activity of systemic inflammation: a decrease in serum levels of IL-1β, IL-6.
Publisher
Astrakhan State Medical University
Reference20 articles.
1. Zabolevaemost vzroslogo naseleniya Rossii v 2022 g. = Morbidity of the adult population of Russia in 2022. Moscow: Ministry of Health of the Russian Federation; 2023; 32 p. (In Russ.).
2. Matyukhin A. V., Emel'yanov V. N. Epidemiological and socio-economic assessment of the importance of community-acquired pneumonia in the Armed Forces of the Russian Federation. Izvestiya rossiyskoy voennomeditsinskoy akademii = Proceedings of the Russian Military Medical Academy. 2019; S1-2: 12–14. (In Russ.).
3. Rendon A., Rendon-Ramirez E. J., Rosas-Taraco A. G. Relevant Cytokines in the Management of Community-Acquired Pneumonia. Current Infectious Disease Reports. 2016; 18 (10). doi: 10.1007/s11908-016-0516-y.
4. Ishiguro T., Takayanagi N., Yamaguchi Sh. et al. Etiology and factors contributing to the severity and mortality of community-acquired pneumonia. Internal Medicine. 2013; 52 (3): 317–324. doi: 10.2169/internalmedicine.52.8830.
5. Chuchalin A. G., Bilichenko T. N., Zverev V. V. et al. Gosudarstvennoye sanitarno-epidemiologicheskoye normirovaniye Rossiyskoy Federatsii. 3.3.1. Vaktsinoprofilaktika. Immunizatsiya polisakharidnoy polivalentnoy vaktsinoy dlya profilaktiki pnevmokokkovoy infektsii = State sanitary and epidemiological regulation of the Russian Federation. 3.3.1. Vaccination. Immunization with polysaccharide polyvalent vaccine for the prevention of pneumococcal infection. The publication is official. Moscow, 2008. 14 p. (In Russ.).